



DEPARTMENT OF ELECTRONICS AND COMMUNICATION ENGINEERING NEWSLETTER

VOL 1 ISSUE 5 MAY 2021

ALUMNI TALK



How to prepare for a job or startup?

The Department of Electronics and Communication Enginneering was organised an online webinar on May 22nd 2021 on the topic "How to prepare a job or startup". Prof. John J Palakkappilly, HOD of ECE welcomed the resource person, teaching staffs, non-teaching staffs and students to the webinar. Mr. Ritheesh Thomas, Software Engineer at Infopark has delivered a wonderful talk on the topic and motivated the students. The students from various departments attended the webinar. Anjana Aneeve, student of S6 ECE has delivered vote of thanks.



POSTER RELEASE


In connection with Techno-cultural Fest 'AGREYA 2K21', the main poster of department was released on 29th May 2021 via Google meet. Prof. John J Palakkappilly released the poster and wished the event to be a grand success. The faculties, non-teaching staffs and students attended the function. There are 3 technical events and 5 cultural events, out of which 5 events are planning to conduct from 7th June 2021 to 13th June 2021 and remaining 3 will be conducted after S8 University examinations. Prof. John J Palakkpilly also inaugurated the Departmental Instagram page "electrosngist21".

WEBINAR ATTENDED

The students of S6 ECE has attended a webinar on the topic **"Electric Event and Future Mobility"** organised by BERIKE INNOVATIONS in collaboration with PRAVAIG, KSEB and KERALA VOVO as a part of TAKSHAK.ONLINE, National Level Technical Fest of Mar Athanasius College of Engineering on 22nd May 2021.

CLASS PTA MEETING


The class PTA meeting of S6 and S8 was conducted on 25th and 26th of May 2021. The main agenda of the meeting is I internal result analyis. Prof. John J Palakkappilly, welcomed the parents and teachers to the meeting. Ms. Hima Paradeep V, Batch Co-ordinator of S6 ECE and Ms. Goipka U K, Ms.Nivya K Venu, Batch Coordinators of S8 ECE shared the performance and progress of the students in first internal examination with the parents. The meeting was concluded with vote of thanks by Ms. Gopika U K, Assoc. Professor, ECE.



WEBINAR ATTENDED BY FACULTIES

Ms. Gopika U K, Associate Professor and Ms. Nivya K Venu, Assistant Professor has attended an online webinar on the Topic "**Black Fungus in Covid-19**" by Dr. Prasobh Stalin , HOD of ENT and Head neck Surgery , Little Flower Hospital, Angamaly was organised by SNMIMT on 29th May 2021.







Ms. Nivya K Venu

STUDENT'S CORNER

DRDO's ANTI-COVID DRUG

Defence Research and Development Organisation's (DRDO) new COVID-19 drug – 2-DG has been recently granted permission for as an adjuvant therapy (treatment given in addition to the primary treatment) in moderate to severe COVID patients by the Drugs Controller General of India (DCGI). This drug has been jointly developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's Laboratories (DRL), Hyderabad.The company claims that the drug can be produced easily in huge quantities as well.



Parvathy A S S6 ECE

The drug essentially comes in a powder form in a sachet and is to be taken twice a day by dissolving it in water, for at least a week. Basically 2-DG stands for 2-deoxy-D glucose, which is essentially a modified glucose, the type that so far has been used in therapeutic treatments as anti-cancer and anti-viral agent.

The technology behind DRDO's 2-DG COVID Drug is that , for the virus to multiply fast in the body it needs glucose for energy. When the virus feeds on this modified glucose for energy, the claim is that it will get arrested which means it will stop from multiplying at that same rate. Defence Research and Development Organisation (DRDO) has said that it should be only used as an additional treatment in moderate to severe COVID patients and not the mild ones. The claims so far is that it leads to faster recovery in COVID patients who are hospitalised. It also claims that it reduces the dependence on oxygen supplement in patients and works against all the variants of the virus.

